This is an old revision of this page, as edited by InShaneee (talk | contribs) at 05:21, 17 December 2005 (rv unsourced, biased info). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 05:21, 17 December 2005 by InShaneee (talk | contribs) (rv unsourced, biased info)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)A prostaglandin is any member of a group of lipid compounds that are derived from fatty acids and have important functions in the animal body. Every prostaglandin contains 20 carbon atoms, including a 5-carbon ring. They are mediators and have a variety of strong physiological effects; although they are technically hormones, they are rarely classified as such.
The prostaglandins together with the thromboxanes form the prostanoid class of fatty acid derivatives; the prostanoid class is a subclass of eicosanoids.
History and name
The name prostaglandin derives from the prostate gland. When prostaglandin was first isolated from seminal fluid in 1936, it was believed to be part of the prostatic secretions. In 1971, it was determined that aspirin-like drugs could inhibit the synthesis of prostaglandins. The biochemists Sune K. Bergström, Bengt I. Samuelsson and John R. Vane jointly received the 1982 Nobel Prize in Physiology or Medicine for their research on prostaglandins.
Biochemistry
Biosynthesis
Prostaglandins are found in virtually all tissues and organs. These are autocrine and paracrine lipid mediators that act upon platelet, endothelium, uterine and mast cells, among others. They are synthesized in the cell from the essential fatty acids
- Gamma-linolenic acid (GLA, an omega-6 EFA) - yielding the series-1 prostaglandins
- Arachidonic acid (AA, omega-6) - yielding series-2
- Eicosapentaenoic acid (EPA, omega-3) - yielding series-3
An intermediate is created by phospholipase-A2, then passed into one of either the cyclooxygenase pathway or the lipoxygenase pathway to form either prostaglandin and thromboxane or leukotriene. The cyclooxygenase pathway produces thromboxane, prostacyclin and prostaglandin D, E and F. The lipoxygenase pathway is active in leukocytes and in macrophages and synthesises leukotrienes. Prostaglandins are released through the prostaglandin transporter on the cell's plasma membrane.
Cyclooxygenases
Prostaglandins are produced following the sequential of AA, GLA or EPA by cyclooxygenases (COX-1 and COX-2) and terminal prostaglandin synthases. The classic dogma is that COX-1 is responsible for the baseline levels of prostaglandins, whereas COX-2 produces prostaglandins through stimulation. However, while COX-1 and COX-2 are both located in the blood vessels, stomach and the kidneys, prostaglandin level are induced by COX-2 in scenarios of inflammation.
Prostaglandin E synthase
Prostaglandin (PG) E2 is generated from the action of prostaglandin E synthases on prostaglandin H2 (PGH2). Several prostaglandin E synthases have been identified. To date, microsomal prostaglandin E synthase-1 emerges as a key enzyme in the formation of PGE2.
Other terminal prostaglandin synthases
Terminal prostaglandin synthases have been identified that are responsible for the formation of other prostaglandins. For example, hematopoietic and lipocailin prostaglandin D synthases (hPGDS and lPGDS) are responsible for the formation of PGD2 from PGH2. Similarly, prostacyclin (PGI2) synthase (PGIS) converts PGH2 into PGI2. A thromboxane synthase (TxAS) has also been idenfitied. While there is evidence that a prostaglandin F synthase (PGFS) may exist, the evidence remains controversial.
Function
There are currently nine known receptors of prostaglandins on various cell types. Prostaglandins ligate a subfamily of cell surface seven transmembrane receptors G protein-coupled receptors. These receptors are termed DP1-2, EP1-4, FP, IP, and TP, corresponding to the receptor that ligates the corresponding prostaglandin (e.g., DP1-2 receptors bind to PGD2). Prostaglandins thus act on a variety of cells such as vascular smooth muscle cells causing constriction or dilation, on platelets causing aggregation or disaggregation and on spinal neurons causing pain. Prostaglandins have a wide variety of actions, including, but not limited to muscular constriction and mediate inflammation. Other effects include calcium movement, hormone regulation and cell growth control. Thromboxane is created in platelets and causes vascular constriction and platelet aggregation. Prostacyclin comes from cells in the blood vessel walls and is antagonistic to thromboxane.
Prostaglandins are potent but have a short half-life before being inactivated and excreted. Therefore, they exert only a paracrine (locally active) or autocrine (acting on the same cell from which it is synthesized) function.
15-deoxy-Δ-PGJ2 (15d-PGJ2) is a PGD2 derivative that acts on PPAR intracellular receptors.
Role in pharmacology
NSAIDs inhibit cyclooxygenase and reduce prostaglandin synthesis. Corticosteroids inhibit phospholipase A2 production by boosting production of lipocortin, an inhibitor protein. Relatively new drugs, known as COX-2 selective inhibitors or coxibs, are used as specific inhibitors of COX-2 (Coxibs). The development of these drugs allowed the circumvention of the negative gastrointestinal effects while effectively reducing inflammation. However, recently, it has been shown that both NSAIDs and Coxibs can raise the risk of myocardial infarction, when taken on a chronic basis for at least 18 months. One emerging hypothesis that may explain the cardiovascular effects is that coxibs create an imbalance in circulating TxA2 and PGI2 levels. An increased in the ratio of TxA2/PGI2 could lead to increased platelet aggregation and dysregulation of platelet homeostatis.
Synthetic prostaglandins are used:
- to induce childbirth or abortion (PGE2 or PGF2, with mifepristone);
- to prevent closure of ductus arteriosus in newborns with particular congenital heart defects
- to prevent and treat peptic ulcers (PGE)
- as a vasodilator in severe Raynaud's phenomenon or ischemia of a limb
- in pulmonary hypertension
- in treatment of glaucoma (as in bimatoprost ophthalmic solution, a synthetic prostamide analog with ocular hypotensive activity)
- to treat erectile dysfunction or in penile rehabilitation following surgery (PGE1 as alprostadil).
External links
- Dorlands Medical Dictionary URL reference on 10/23/05.
- Medscape Early Penile Rehabilitation Helps Reduce Later Intractable ED URL reference on 10/23/05.